Stock XOMA XOMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

XOMA Corporation Stock

Equities

XOMA

US98419J2069

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
25.82 USD +1.89% Intraday chart for XOMA Corporation +0.70% +39.57%
Apr. 30 XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million. CI
Apr. 29 Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target MT

Financials (USD)

Sales 2024 * 14M Sales 2025 * 23.57M Capitalization 300M
Net income 2024 * -27M Net income 2025 * -19M EV / Sales 2024 * 21.5 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 12.7 x
P/E ratio 2024 *
-10.8 x
P/E ratio 2025 *
-15.4 x
Employees 13
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.58%
More Fundamentals * Assessed data

Chart XOMA Corporation

Dynamic Chart

Latest news about XOMA Corporation

XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million. CI
Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target MT
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc.. CI
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sector Update: Health Care Stocks Advance Friday Afternoon MT
XOMA Agrees to Acquire Kinnate Biopharma MT
XOMA Corporation entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. for approximately $120 million. CI
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million MT
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million. CI
XOMA Names Owen Hughes CEO, Jack Wyszomierski Chairman; to Make $1 Million Milestone Payment MT
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol DJ
Xoma Names Owen Hughes as Chief Executive Officer CI
Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors CI
XOMA Authorizes $50 Million Share Buyback Program MT
XOMA Authorizes $50 Million Share Buyback Program MT
More news

Analyst Recommendations on XOMA Corporation

Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target MT
HC Wainwright Adjusts Price Target on XOMA to $74 From $69, Maintains Buy Rating MT
XOMA : Wedbush Suspended Coverage on XOMA MT
XOMA : HC Wainwright Adjusts XOMA's Price Target to $69 from $56, Keeps Buy Rating MT
XOMA : Aegis Capital Adjusts XOMA Price Target to $56 From $60, Maintains Buy Rating MT
More recommendations

Press releases XOMA Corporation

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% AQ
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) AQ
XOMA : Acquisition/Asset Disposal - Form 8-K PU
XOMA Corporation Announces Closing of Tender Offer AQ
XOMA Declares Quarterly Preferred Stock Dividends AQ
More press releases

News in other languages on XOMA Corporation

Obseva: Organon rétrocède la licence pour Ebopiprant, paiement d'étape éteint
Obseva: Organon gibt Lizenz für Ebopiprant zurück - Meilensteinanspruch erlischt
Kuros: le déploiement commercial du Magnetos a creusé le déficit en 2022
Obseva réduit la voilure autour de ses actifs restants
Obseva: la demande de retrait de sursis concordataire est acceptée
More news

Quotes and Performance

1 day+1.89%
1 week+0.70%
Current month+1.89%
1 month+2.26%
3 months+25.34%
6 months+34.97%
Current year+39.57%
More quotes

Highs and lows

1 week
25.02
Extreme 25.0199
26.74
1 month
23.99
Extreme 23.99
27.00
Current year
18.57
Extreme 18.5701
27.00
1 year
13.48
Extreme 13.48
27.00
3 years
13.48
Extreme 13.48
39.02
5 years
12.47
Extreme 12.47
46.32
10 years
3.96
Extreme 3.96
119.00
More quotes

Managers and Directors - XOMA Corporation

Managers TitleAgeSince
Owen Hughes CEO
 Chief Executive Officer 49 22-12-31
Thomas Burns DFI
 Director of Finance/CFO 50 06-08-13
Bradley Sitko CIO
 Chief Investment Officer 43 23-01-02
Members of the board TitleAgeSince
Heather Franklin BRD
 Director/Board Member 58 21-08-05
Jack Wyszomierski CHM
 Chairman 68 10-08-25
Joseph Limber BRD
 Director/Board Member 71 12-12-11
More insiders

ETFs positioned on XOMA Corporation

Name Weight AuM 1st Jan change Investor Rating
ROYCE QUANT SMALL-CAP QUALITY VALUE ETF - USD ETF Royce Quant Small-Cap Quality Value ETF - USD
0.22% 27 M€ -5.94% -
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +1.32% -
More ETFs positioned on XOMA Corporation

Quotes

Date Price Change Volume
24-05-01 25.82 +1.89% 13,366
24-04-30 25.34 -4.38% 10,205
24-04-29 26.5 +4.29% 12,311
24-04-26 25.41 +0.20% 6,127
24-04-25 25.36 -1.09% 6,783

Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT

More quotes

Company Profile

XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Sector
Biotechnology & Medical Research
Calendar
2024-05-06 - Q1 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Ratings for XOMA Corporation

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
25.82 USD
Average target price
57 USD
Spread / Average Target
+120.76%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
XOMA CORPORATION Stock XOMA Corporation
+39.57% 300M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.17% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.87% 97.47B
ARGENX SE Stock argenx SE
+3.90% 22.25B
BIONTECH SE Stock BioNTech SE
-14.77% 21.68B
GENMAB A/S Stock Genmab A/S
-9.16% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.55% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.75% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. XOMA Stock